Catheter Removal Versus Retention in the Management of Catheter-associated Enterococcal Bloodstream Infections
Overview
Affiliations
Background: Enterococci are an important cause of central venous catheter (CVC)-associated bloodstream infections (CA-BSI). It is unclear whether CVC removal is necessary to successfully manage enterococcal CA-BSI.
Methods: A 12-month retrospective cohort study of adults with enterococcal CA-BSI was conducted at a tertiary care hospital; clinical, microbiological and outcome data were collected.
Results: A total of 111 patients had an enterococcal CA-BSI. The median age was 58.2 years (range 21 to 94 years). There were 45 (40.5%) infections caused by Entercoccus faecalis (among which 10 [22%] were vancomycin resistant), 61 (55%) by Enterococcus faecium (57 [93%] vancomycin resistant) and five (4.5%) by other Enterococcus species. Patients were treated with linezolid (n=51 [46%]), vancomycin (n=37 [33%]), daptomycin (n=11 [10%]), ampicillin (n=2 [2%]) or quinupristin/dalfopristin (n=2 [2%]); seven (n=6%) patients did not receive adequate enterococcal treatment. Additionally, 24 (22%) patients received adjunctive gentamicin treatment. The CVC was retained in 29 (26.1%) patients. Patients with removed CVCs showed lower rates of in-hospital mortality (15 [18.3%] versus 11 [37.9]; P=0.03), but similar rates of recurrent bacteremia (nine [11.0%] versus two (7.0%); P=0.7) and a similar post-BSI length of hospital stay (median days [range]) (11.1 [1.7 to 63.1 days] versus 9.3 [1.9 to 31.8 days]; P=0.3). Catheter retention was an independent predictor of mortality (OR 3.34 [95% CI 1.21 to 9.26]).
Conclusions: To the authors' knowledge, the present article describes the largest enterococcal CA-BSI series to date. Mortality was increased among patients who had their catheter retained. Additional prospective studies are necessary to determine the optimal management of enterococcal CA-BSI.
Heybati K, Seeger R, Thyagu S, Piticaru J, Ahluwalia N, Munshi L Ann Hematol. 2022; 101(11):2515-2524.
PMID: 36107204 DOI: 10.1007/s00277-022-04969-7.
Katip W, Oberdorfer P Pharmaceutics. 2021; 13(9).
PMID: 34575453 PMC: 8464995. DOI: 10.3390/pharmaceutics13091378.
Management of enterococcal central line-associated bloodstream infections in patients with cancer.
Awadh H, Chaftari A, Khalil M, Fares J, Jiang Y, Deeba R BMC Infect Dis. 2021; 21(1):643.
PMID: 34225651 PMC: 8256598. DOI: 10.1186/s12879-021-06328-9.
Muff S, Tabah A, Que Y, Timsit J, Mermel L, Harbarth S Infect Dis Ther. 2021; 10(3):1591-1605.
PMID: 34169480 PMC: 8322176. DOI: 10.1007/s40121-021-00464-0.
Dubler S, Lenz M, Zimmermann S, Richter D, Weiss K, Mehrabi A Antimicrob Resist Infect Control. 2020; 9(1):22.
PMID: 32005223 PMC: 6995054. DOI: 10.1186/s13756-020-0683-3.